SG Americas Securities LLC Takes $222,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)

SG Americas Securities LLC purchased a new stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 59,775 shares of the company’s stock, valued at approximately $222,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Sanctuary Advisors LLC acquired a new position in ImmunityBio in the second quarter valued at about $233,000. B. Riley Wealth Advisors Inc. acquired a new position in ImmunityBio in the second quarter valued at about $515,000. Algert Global LLC acquired a new position in ImmunityBio in the second quarter valued at about $86,000. Susquehanna Fundamental Investments LLC acquired a new position in ImmunityBio in the second quarter valued at about $147,000. Finally, The Manufacturers Life Insurance Company lifted its position in ImmunityBio by 15.6% in the second quarter. The Manufacturers Life Insurance Company now owns 94,367 shares of the company’s stock valued at $596,000 after buying an additional 12,738 shares during the last quarter. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Price Performance

NASDAQ IBRX opened at $3.49 on Wednesday. The firm’s 50-day moving average is $3.70 and its two-hundred day moving average is $5.39. ImmunityBio, Inc. has a 12 month low of $1.28 and a 12 month high of $10.53. The stock has a market capitalization of $2.41 billion, a P/E ratio of -3.20 and a beta of 1.02.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.53 million. As a group, analysts anticipate that ImmunityBio, Inc. will post -0.86 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Piper Sandler decreased their target price on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research report on Monday, August 19th.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.